Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-306 vs sevelamer for hyperphosphatemia in hemodialysis
CTR20230189Phase 2Completed
- Sponsor
- Libang Pharmaceutical
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EOS789 in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Libang Pharmaceutical. Primary endpoints: Change in serum phosphorus from baseline to end of treatment or before start of rescue therapy, Nature, incidence, and severity of serious and non-serious adverse events and 1 more. Started Jan 2023; status: completed.
02
Drugs
EOS789
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20230189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230189.